Tobacco Asia

72 tobaccoasia Issue 2, 2026 March / April Biohackers, entrepreneurs, and health in- fluencers increasingly experiment with low-dose nicotine products as part of productivity "stacks" – combinations of supplements or peptides de- signed to work synergistically to enhance focus, mental clarity, and physical performance. Products now range far beyond traditional tobacco. Nicotine appears in patches, gum, loz- enges, pouches and even functional beverages, of- ten marketed as tools for energy, concentration, or lifestyle optimization. Startups have leaned into the concept of nic- otine as a performance aid. Some companies sell low-dose pouches designed for athletes or profes- sionals who want a controlled stimulant similar to caffeine but with a different cognitive profile. Sales growth in nicotine pouches and other smokeless formats reflects this cultural shift. Dis- creet, tobacco-free products have made nicotine use less associated with smoking and more com- patible with modern wellness aesthetics. In many ways, nicotine now occupies a space similar to caf- feine: a stimulant integrated into daily routines to support work, exercise and mental performance. Harm reduction and changing perceptions The broader "nicotine renaissance" also aligns with the global harm-reduction movement. Many scientists and public health research- ers now emphasize that nicotine itself does not cause cancer, that the primary health damage asso- ciated with smoking stems from combustion and the toxic chemicals in cigarette smoke rather than nicotine alone. As a result, alternative nicotine delivery systems—from vapor products to pouch- es—have gained support among harm-reduction advocates as lower-risk options for adult smokers unable or unwilling to quit nicotine entirely. That perspective has also started to gain traction among some clinicians who argue that de- cades of messaging blurred the difference between nicotine and smoking. As a result, public percep- tion has begun to shift, although progress remains uneven. Surveys conducted in several countries continue to show widespread misunderstanding about nicotine itself. A large study by Weiger et al, Beliefs and Characteristics Associated With Believ- ing Nicotine Causes Cancer: A Descriptive Analysis to Inform Corrective Message Content and Priority Audi- ences published in Nicotine & Tobacco Research in 2022 found that a majority of adults in the US incorrectly believe nicotine directly causes can- cer, even though decades of research attribute the overwhelming health risks of smoking to the toxic chemicals produced during combustion rather than nicotine itself. Public-health experts say this confusion partly reflects decades of anti-smoking campaigns that deliberately linked nicotine with smoking addiction to discourage tobacco use. While that strategy played a role in reducing smok- ing prevalence, many scientists now argue it also blurred the scientific distinction between nicotine and the thousands of toxic compounds found in cigarette smoke. Researchers increasingly empha- size that correcting these misconceptions will play a critical role in helping both healthcare profes- sionals and consumers better understand harm- reduction strategies and the risk profile of modern nicotine products. Rewriting the nicotine narrative The emerging conversation around nicotine re- flects a broader trend in health science: reassessing substances once viewed in purely negative terms. Just as researchers reevaluated caffeine, psy- chedelics, and cannabis in recent years, nicotine seemingly now receives renewed scrutiny — not as a moral symbol, but as a biologically active com- pound with complex effects. For decades, public health messaging sim- plified nicotine into a villain. Today, however, advances in nicotine delivery technology and neuroscience have reopened the discussion. The compound once synonymous with addiction now sits at the center of debates about harm reduction, cognitive enhancement, and even wellness culture. Whether nicotine ultimately finds a place alongside caffeine as a socially accepted stimulant remains uncertain. But one thing has become clear: the scientific and cultural narrative surrounding nicotine has begun to evolve — and the story is far from finished. Low-dose nicotine products are increasingly used in productivity "stacks"—blends of supplements or peptides aimed at enhancing focus, clarity, and performance. Credit: Anna Shvets, Pexels.

• Cover